Evaluation of Cytomegalovirus Infections in Liver Transplant Recipients Under Universal Prophylaxis: A Single Centre Experience
Open Access
- 8 September 2021
- journal article
- research article
- Published by Briefland in Hepatitis Monthly
- Vol. 21 (6)
- https://doi.org/10.5812/hepatmon.115370
Abstract
Background: Cytomegalovirus (CMV) is one of the leading viral agents that can pave the way for serious complications and organ damage in solid organ transplant (SOT) recipients after transplantation. Strategies have been developed to protect at-risk patients from CMV infection following transplantation. Since more than 90% of adults in Turkey were positive for CMV IgG, universal CMV prophylaxis was applied, and the results were evaluated. Objectives: This study aimed to evaluate the results of universal CMV prophylaxis after liver transplantation in the long term. Methods: A total of 1,090 liver transplant patients were evaluated in terms of CMV infection in the Organ Transplantation Institute of Inonu University, Malatya, Turkey, from October 2014 to December 2019. In order to identify the CMV infections, quantitative nucleic acid amplification (QNAT) was used to detect potential CMV DNA. The cut-off value of CMV DNA was determined to be 1000 copies/mL after transplantation. Results: According to the clinical and laboratory assessments, 33 (3%) patients were diagnosed with CMV infection, and 25 (2.3%) patients were evaluated as possibly having CMV syndrome. Also, eight of the 33 patients were assessed as having end-organ CMV disease and 25 as probable CMV syndrome. In the late period following prophylaxis, CMV infection was observed in 10 (0.9%) cases. The infection rate after prophylaxis (0.9%) was lower than the infection rate (2.1%) seen during prophylaxis. Conclusions: Close clinical follow-up with CMV prophylaxis and strict monitoring of CMV DNA by determining a specific cut-off point are important in the follow-up of liver transplant patients. Keywords Quantitative Nucleic Acid Amplification (QNAT) Probable CMV Syndrome Liver Transplantation CMV Prophylaxis, End-Organ CMV disease Cytomegalovirus InfectionKeywords
This publication has 16 references indexed in Scilit:
- Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipientsTransplant Infectious Disease, 2016
- Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ TransplantationTransplantation, 2013
- High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapyJournal of Medical Virology, 2013
- Quantification of cytomegalovirus DNA by a fully automated real-time PCR for early diagnosis and monitoring of active viral infection in solid organ transplant recipientsJournal of Clinical Virology, 2013
- Cytomegalovirus infection: Its incidence and management in cytomegalovirus‐seropositive living related liver transplant recipients: A single‐center experienceLiver Transplantation, 2012
- Impact of a Preemptive Strategy After 3 Months of Valganciclovir Cytomegalovirus Prophylaxis in Kidney Transplant RecipientsTransplantation, 2011
- Review of cytomegalovirus seroprevalence and demographic characteristics associated with infectionReviews in Medical Virology, 2010
- Cytomegalovirus Seroprevalence in the United States: The National Health and Nutrition Examination Surveys, 1988–2004Clinical Infectious Diseases, 2010
- Update in Infectious Diseases in Liver Transplant RecipientsClinics in Liver Disease, 2007
- Seroprevalence of cytomegalovirus infection among children and females in Ankara, Turkey, 1995.Pediatrics International, 1999